RadNet, Inc. Delivers Record Fourth Quarter 2025 Results, Announces Bold 2026 Guidance and Strategic AI Acquisition

Key Financial Highlights

• Record Fourth Quarter Revenue: RadNet reported Q4 2025 total company revenue of \$547.7 million, a 14.8% increase from Q4 2024’s \$477.1 million. Digital Health segment revenue surged 48.2% to \$27.9 million, up from \$18.9 million.
• Record Adjusted EBITDA: Q4 Adjusted EBITDA hit \$87.7 million, up 16.9% from \$75.0 million in the prior year. Digital Health segment Adjusted EBITDA grew by 8.9% to \$4.9 million.
• Margin Improvement: Adjusted EBITDA margins increased by 29 basis points to 16.0% (Q4 2024: 15.7%).
• Adjusted Earnings Per Share: Adjusted EPS was \$0.23 in Q4 2025 vs. \$0.24 in Q4 2024.
• Advanced Imaging Volume Growth: Aggregate MRI, CT, and PET/CT procedure volumes rose 14.1%, with same-center volumes up 9.6% year-over-year.

Full-Year 2025 Performance

• Annual Revenue: Total company revenue for 2025 reached \$2,040.2 million, up 11.5% from 2024.
• Adjusted EBITDA: Full-year Adjusted EBITDA was \$300.2 million (+7.4%).
• Digital Health Segment: Annual revenue (incl. intersegment) was \$92.7 million (+41.1%), Adjusted EBITDA \$15.5 million.
• Annual Recurring Revenue (ARR): Digital Health ARR at year-end was \$75.4 million, representing 81.3% of segment revenue.
• Net Loss: Unadjusted, RadNet reported a net loss of \$18.7 million for 2025, compared to net income of \$2.8 million in 2024. Diluted net loss per share: \$(0.25) (2024: \$0.04).

2026 Guidance: Strong Growth Ahead

Imaging Center Segment

• Total Net Revenue: \$2,325–\$2,375 million (growth of 17–19%)
• Adjusted EBITDA: \$335–\$348 million (growth of 18–22%)
• Free Cash Flow: \$105–\$115 million (growth of 29–41%)
• Capital Expenditures: \$165–\$175 million
• Cash Interest Expense: \$45–\$50 million

Digital Health Segment

• Total Net Revenue: \$135–\$145 million (growth of 46–56%)
• Adjusted EBITDA (before non-capitalized R&D): \$10–\$12 million
• Non-Capitalized R&D: \$17–\$19 million
• Free Cash Flow (before non-capitalized R&D): \$(1)–\$3 million
• Free Cash Flow (after non-capitalized R&D): \$(17)–\$(19) million
• ARR: Expected to approach or exceed \$140 million by year end.
• Revenue Mix: Proportion of Digital Health revenue from RadNet’s Imaging Center segment to decline from ~45% in 2025 to ~33% in 2026, reflecting accelerated external growth.

Strategic Note: Guidance assumes growth despite labor cost headwinds and severe winter weather impacts in early 2026.

Strategic Developments & Price-Sensitive News

• Acquisition of Gleamer SAS (Paris): Announced in Q4, this acquisition positions RadNet’s Digital Health division as holding what management believes to be the world’s most comprehensive portfolio of clinical AI solutions. Gleamer adds musculoskeletal AI capabilities, complementing prior acquisitions (iCAD, See-Mode, CIMAR).
• AI Strategy: RadNet is investing heavily in DeepHealth technology (TechLive™, See-Mode, generative AI tools) to drive automation, efficiency, and productivity. These innovations are expected to improve clinical outcomes, service levels, and capacity—addressing critical industry challenges (labor shortages, capacity constraints, radiologist workloads).
• FDA Clearances: At least four FDA clearances expected in 2026 across mammography, lung, prostate, thyroid, brain, and musculoskeletal AI solutions.
• Aggressive Expansion: Significant investments in new centers and acquisitions, with 418 owned/operated outpatient centers at year-end. Continued same-center performance improvements, reimbursement efforts, and de novo openings anticipated.

Operational Details

• Procedure Mix: Q4 2025 advanced imaging (MRI, CT, PET/CT) accounted for a larger share of overall volumes, with MRI up 15.8%, CT up 10.3%, and PET/CT up 28.3% year-over-year. Routine imaging increased 7% overall.
• Payor Mix: Commercial insurance comprised 57.1% of Q4 2025 revenue, Medicare 26.6%, capitation 5.8%, Medicaid 2.6%, Workers Comp/Personal Injury 2.2%, Other 8.6% (including Digital Health revenue).
• Modality Mix: MRI represented 38.2% of Q4 revenue, CT 15.4%, PET/CT 9.2%, Mammography 15.5%, Ultrasound 13.3%, X-ray 5.1%, Nuclear Medicine 0.8%, Other 2.5%.

Balance Sheet & Liquidity

• Cash & Cash Equivalents: \$767.2 million at December 31, 2025 (up from \$740.0 million in 2024).
• Total Assets: \$3.76 billion (2024: \$3.29 billion)
• Stockholders’ Equity: \$1.09 billion (2024: \$902 million)
• Noncontrolling Interests: \$266 million (2024: \$231 million)
• Debt: \$1.09 billion in notes payable (long-term), up from \$992 million in 2024.

One-Time and Unusual Items in Q4 2025

• Unusual/One-Time Expenses: Severance (\$531k), lease abandonment (\$233k), leases for centers not yet opened (\$788k), acquisition transaction costs (\$2.3m), loss on sale/disposal of equipment (\$6.5m), DeepHealth R&D expense (\$6.3m), interest rate swap loss (\$679k), tax provision adjustment (\$5.7m).
• Adjusted Earnings: After adjustments, total company adjusted earnings were \$18.1 million, diluted adjusted EPS \$0.23.
• Unadjusted Net Loss: Q4 2025 net loss of \$0.6 million (Q4 2024: net income of \$5.3 million), diluted net loss per share \$(0.01).

Investor Considerations & Risks

• Forward-Looking Statements: Management’s guidance and growth projections are subject to risks, including economic conditions, labor costs, capital availability, reimbursement rates, interest rate volatility, regulatory changes, political environment, industry-wide adoption of AI, and cybersecurity threats.
• Capital Expenditure: Aggressive investments in expansion and technology, including the acquisition of Gleamer SAS, may impact short-term profitability but are intended to drive long-term growth.
• Debt & Liquidity: RadNet’s ability to service debt and remain compliant with covenants remains a focus point.
• AI Adoption: The success of DeepHealth and associated AI solutions will be critical to RadNet’s future competitive position.

Conference Call

RadNet management will host a conference call on March 2, 2026, at 10:30 a.m. ET to discuss these results and outlook. Investors may access the call via phone or webcast, with archived replays available.

Conclusion

RadNet’s Q4 2025 results and 2026 guidance reflect robust growth, strategic investment in AI, and significant expansion. The acquisition of Gleamer SAS and anticipated FDA clearances position RadNet as a leader in clinical AI for diagnostic imaging. The company’s aggressive guidance for 2026, combined with its technology-driven vision, could be highly price-sensitive for investors. However, risks from labor costs, weather impacts, and ongoing investments should be considered.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Forward-looking statements are subject to risks and uncertainties; actual results may differ materially. Investors should review RadNet’s official filings and consult with financial professionals before making any investment decisions.

View RadNet, Inc. Historical chart here